100% Quality Guarantee
PhD-Level Technical Support
Key Features

Human SIGLEC2/CD22 Recombinant Protein (RPES4218)

SKU RPES4218
Product Type Recombinant Protein
Species Human
Application Area Immune Receptors
€159 - €357

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human SIGLEC2/CD22 Recombinant Protein

CD22 is a member of the immunoglobulin superfamily; SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells; and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions; signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow; blood; and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR); CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors; the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR; and this in turn is governed by the binding of its extracellular domain to alpha2;6-linked sialic acid ligands. However; genetic studies in mice reveal that some CD22 functions are regulated by ligand binding; whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity; while CD22 inhibits CD19 phosphorylation via SHP-1.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose